Currently receiving at least one treatment for SLE
You may not be if
Has active, severe lupus nephritis as defined either by the immediate need for cyclophosphamide treatment or by renal BILAG A
Has active, severe, neuropsychiatric SLE, defined as neuropsychiatric BILAG A
Has been treated with corticosteroids (CS) at a dose of \>20 mg of prednisone equivalent/day for \> 7 consecutive days
Is currently receiving or has received pulse dose CS (≥ 250 mg prednisone equivalent/day)
Has received potent immunosuppressive drugs
Has received abatacept, sifalimumab, rontalizumab, anifrolumab, belimumab, tumor necrosis factor (TNF) antagonists or another registered or investigational biological therapy
Has received anti-B-cell therapy (e.g., rituximab, epratuzumab)
Has frequent recurrences of oral or genital herpes simplex lesions
Is at high risk of significant infection and/or has any current signs or symptoms of infection at entry or has received intravenous antibiotics
Has received any live vaccine
Has used any investigational or non-registered product or any investigational or non-registered vaccine
Is high-risk human papilloma virus (HPV) positive by rRT-qPCR on a cervical swab
Has cytological abnormalities ≥ high grade squamous intraepithelial lesions (HSIL) on a cervical swab
Clareo Health | Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
